Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

Similar articles for PubMed (Select 23204224)


Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma.

Shakya R, Gonda T, Quante M, Salas M, Kim S, Brooks J, Hirsch S, Davies J, Cullo A, Olive K, Wang TC, Szabolcs M, Tycko B, Ludwig T.

Cancer Res. 2013 Jan 15;73(2):885-96. doi: 10.1158/0008-5472.CAN-12-1880. Epub 2012 Nov 29.


Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases.

Müerköster SS, Werbing V, Koch D, Sipos B, Ammerpohl O, Kalthoff H, Tsao MS, Fölsch UR, Schäfer H.

Int J Cancer. 2008 Oct 15;123(8):1751-60. doi: 10.1002/ijc.23703.


Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.

Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y, Maeda S, Ikenoue T, Tateishi K, Wright CV, Koike K, Omata M, Moses HL.

J Clin Invest. 2011 Oct;121(10):4106-17. doi: 10.1172/JCI42754. Epub 2011 Sep 19.


Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ.

Cancer Cell. 2014 Jun 16;25(6):735-47. doi: 10.1016/j.ccr.2014.04.021. Epub 2014 May 22.


Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.

Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL.

BMC Cancer. 2008 May 2;8:128. doi: 10.1186/1471-2407-8-128.


Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model.

Siddique HR, Liao DJ, Mishra SK, Schuster T, Wang L, Matter B, Campbell PM, Villalta P, Nanda S, Deng Y, Saleem M.

Int J Cancer. 2012 Oct 1;131(7):1720-31. doi: 10.1002/ijc.27409. Epub 2012 Feb 18.


Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation.

Schwarz RE, Awasthi N, Konduri S, Caldwell L, Cafasso D, Schwarz MA.

Cancer Biol Ther. 2010 Apr 15;9(8):632-9. Epub 2010 Apr 20.


Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.

Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P, Bartsch DK, Langer P, Chiblak S, Dürr A, Höfler H, Klöppel G, Müller-Decker K, Brielmeier M, Esposito I.

J Pathol. 2012 Apr;226(5):723-34. doi: 10.1002/path.3017. Epub 2012 Jan 17.


Early requirement of Rac1 in a mouse model of pancreatic cancer.

Heid I, Lubeseder-Martellato C, Sipos B, Mazur PK, Lesina M, Schmid RM, Siveke JT.

Gastroenterology. 2011 Aug;141(2):719-30, 730.e1-7. doi: 10.1053/j.gastro.2011.04.043. Epub 2011 Apr 28.


BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2012 Dec;11(12):2644-53. doi: 10.1158/1535-7163.MCT-12-0447. Epub 2012 Oct 9.


miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.

Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu P, Wei J, Jiang K, Miao Y.

Oncol Rep. 2013 May;29(5):1769-76. doi: 10.3892/or.2013.2297. Epub 2013 Feb 21.


Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer.

Geismann C, Morscheck M, Koch D, Bergmann F, Ungefroren H, Arlt A, Tsao MS, Bachem MG, Altevogt P, Sipos B, Fölsch UR, Schäfer H, Müerköster SS.

Cancer Res. 2009 May 15;69(10):4517-26. doi: 10.1158/0008-5472.CAN-08-3493. Epub 2009 May 12.


A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.

Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJ, Jian KY, Huang SS, Jiang SS, Shan YS, Lin PW, Shen YY, Lee MT, Chan TS, Chang CC, Chen CH, Chang IS, Lee YL, Chen LT, Tsai KK.

Gastroenterology. 2013 Nov;145(5):1110-20. doi: 10.1053/j.gastro.2013.07.040. Epub 2013 Jul 27.


Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.

Mohammed A, Qian L, Janakiram NB, Lightfoot S, Steele VE, Rao CV.

Int J Cancer. 2012 Oct 15;131(8):1951-62. doi: 10.1002/ijc.27456. Epub 2012 Mar 14.


The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.

Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H.

Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):454-67. doi: 10.1038/nrgastro.2012.115. Epub 2012 Jun 19. Review.


Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.

Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):E1275-84. doi: 10.1073/pnas.1111079108. Epub 2011 Nov 14.


Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine.

Cecconi D, Astner H, Donadelli M, Palmieri M, Missiaglia E, Hamdan M, Scarpa A, Righetti PG.

Electrophoresis. 2003 Dec;24(24):4291-303.


Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.

Motoda N, Matsuda Y, Onda M, Ishiwata T, Uchida E, Naito Z.

Int J Oncol. 2011 Jan;38(1):133-43.


A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.

Sempere LF, Gunn JR, Korc M.

Cancer Biol Ther. 2011 Aug 1;12(3):198-207. Epub 2011 Aug 1.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk